Clinical Trial Update: Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports on the safety and immunomodulatory effects of alemtuzumab (Campath) in pediatric kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Transplantation

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Kidney Failure, Chronic, Kidney Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2012-10-25